Insider transactions

Roger Jeffs

CIK 1231615 · Chief Executive Officer · last filed 2026-10-13

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$83.12M
Companies
6
Total Filings
376
Lifetime Open-Market Net
-$194.84M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

UTHR price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LQDA Chief Executive Officer 1,190,854 $47.91 $57.05M -$33.38M 40 2026-10-13
AXSM Director 105,565 $133.53 $14.10M -$15.63M 31 2026-06-11
ALBIREO PHARMA, INC. (ALBO) Delisted Director — $44.15 — $0 6 2021-06-28
Dova Pharmaceuticals Inc. (DOVA) Delisted Director 0 — — $701.9K 7 2019-11-12
SANGAMO THERAPEUTICS, INC (SGMO) Delisted Director 9,908 $0.18 $1.8K $100.5K 3 2018-09-07
UTHR President & Co-CEO 20,486 $584.12 $11.97M -$146.64M 268 2016-03-15

Recent Filings · Page 4 of 38

376 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-09-02 AXSM Sell (S) −13,464 -$1.67M EDGAR
2025-08-29 AXSM Notice (144) −20,000 -$2.43M EDGAR
2025-08-29 AXSM Sell (S) −60,000 -$7.30M EDGAR
2025-08-28 AXSM Notice (144) −20,000 -$2.43M EDGAR
2025-08-27 AXSM Notice (144) −20,000 -$2.45M EDGAR
2025-08-26 AXSM Notice (144) −20,000 -$2.40M EDGAR
2025-08-26 AXSM Sell (S) −36,694 -$4.41M EDGAR
2025-08-22 AXSM Notice (144) −16,694 -$2.00M EDGAR
2025-07-15 LQDA Mixed −6,419 -$289.2K EDGAR
2025-07-15 LQDA Mixed −6,419 -$289.2K EDGAR
Showing 31–40 of 376
Page 4 of 38
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.